Comparisons of induction chemotherapy (IC) against upfront chemoradiation (CRT) for locally advanced head and neck cancer (LA-HNSCC) have demonstrated no differences except greater toxicity with IC. Effective induction regimens that are less toxic are therefore warranted. To inform future efforts with IC, we present our institutional experience comparing a less toxic IC regimen to CRT.
I
t is estimated that in 2013, over 53,000 individuals will be diagnosed with head and neck cancer in the United States, with an estimated 11,500 deaths. 1 Approximately 47% of patients will present with advanced stage disease. 1 One established treatment approach for patients with locally advanced squamous cell carcinoma of the head and neck (LA-HNSCC) is organ preservation with concurrent chemoradiotherapy (CRT). [2] [3] [4] [5] [6] On the basis of the results of the TAX studies, 7, 8 induction chemotherapy (IC) followed by RT or CRT became a second widely used approach in the treatment of these patients. The TAX studies compared one induction regimen (docetaxel, cisplatin, fluorouracil; TPF) versus another (cisplatin, fluorouracil; PF). Direct, randomized comparisons of IC versus CRT have been attempted (most notably the DeCIDE and PARADIGM trials), but their interpretation has been complicated by poor accrual, premature study closure, and significant acute toxicity secondary to IC. Most important, the hope for favorable impact on overall survival by the addition of IC to CRT has not been realized in the data analyzed to date, 9-11 despite a decrease in distant failures observed with IC in DeCIDE. 9 Given the very real toxicities of docetaxel-based IC, a number of recent efforts have focused on developing equally effective, but less toxic IC regimens. One of the most promising regimens evaluated to date consists of weekly cetuximab, carboplatin, and paclitaxel (PCC), which in nonrandomized phase II clinical trials has demonstrated very high response rates, similar to those seen with TPF, but with less toxicity. 12, 13 Given the high hospitalization and toxicity rates observed with the TPF regimen, a decision was made by the medical oncologists at our institution to treat patients with PCC induction beginning in 2008. The published results of our institutional experience with PCC induction 14 demonstrate response rates (97% response rate: 30% complete response, 67% partial response) at least comparable with that observed in the 2 phase II studies of this regimen. 12, 13 However, a comparison of PCC induction followed by CRT versus upfront CRT has not yet been made.
There are numerous theoretical factors for and against the use of IC. Proponents of induction therapy cite the ability to deliver multiple agents at higher doses pre-CRT or RT, with the thought that this may salvage a subset of patients who otherwise would develop systemic cancer dissemination. Other arguments for induction include the ability to assess biological response in adaptive treatment paradigms (eg, referring the nonresponding patients to radical surgery) and even reduce the volume of disease that would need to be irradiated. Opponents of induction cite concerns about delaying the onset of definitive radiation, potential compromises in the delivery of CRT secondary to the acute toxicity from induction, and changes in tumor vasculature and microenvironment caused by IC, which could promote radiation resistance. These concerns are not without merit, given worse locoregional control with IC compared with CRT shown in the Pignon meta-analysis of chemotherapy in head and neck cancer. 2 Here we present the retrospective results of our institutional experience comparing IC (with cetuximab, carboplatin, and paclitaxel) versus upfront CRT.
MATERIALS AND METHODS
This was an Institutional Review Board-approved retrospective review of consecutive patients with AJCC (7th edition) 15 , with standard premedications of dexamethasone (12 mg IV), diphenhydramine (50 mg IV), and ondansetron (24 mg IV). Treatment cycles were repeated weekly for up to 8 weeks and doses were withheld or modified at the provider's discretion depending on the types of toxicities experienced.
Radiotherapy was initiated approximately 3 weeks after completion of IC. Target volumes, duration of therapy, and total radiation dose were determined by the treating radiation oncologist based on the standard of care. For all patients receiving IC, target delineation of the gross tumor volumes at the primary site and involved neck nodes were based on pre-IC disease extent, as captured on a PET-CT simulation performed before initiation of IC. An intensity-modulated radiation therapy technique with dose painting was used for all patients, with a total dose of approximately 70 Gy delivered over 7 weeks (1 fraction/d, 5 d/wk).
Concurrent therapy during radiotherapy was determined at the discretion of the provider. Depending on the performance status and prior toxicities, the regimens used included either high-dose cisplatin (100 mg/m . Chemotherapy modifications that were made during radiation were made irrespective of whether a patient received IC or not, and were based on standard guidelines and routine laboratory evaluation of blood counts and kidney function. These standardized approaches were reflective and consistent of how the various trials of the respective regimens were performed. Because the therapy was given with curative intent (IC or CRT), all efforts were made within standard guidelines to avoid dose reductions/deletions.
Data Collection
Once patients were identified, we reviewed the electronic medical charts to extract data for baseline patient characteristics (age, marital status, sex, performance status, smoking history), disease characteristics (T stage, N stage, gross tumor volume, p16 status, tumor subsite), treatment, and toxicity data (total treatment days, whether IC was given, weight loss during treatment, need for PEG at last follow-up, and changes in radiation or chemotherapy dose, schedule or regimen due to toxicity). Initial radiation and medical oncology consultation notes were reviewed to determine why the patients in the IC group received induction (such as concern for tumor bulk or physician preference). Many patients in both groups had unknown p16 status, as they were treated at a time before p16/HPV testing became the standard of care at our institution. Imaging studies for those patients with locoregional recurrence were reviewed and fused with the initial radiation treatment plan to determine whether the recurrence was in-field versus marginal.
Statistical Analysis
The w 2 tests and independent 2-sample t tests were used to assess differences in demographic, disease, treatment, and toxicity variables between the IC and CRT groups. Differences in overall survival, distant metastasis-free survival, and locoregional control between the IC and CRT groups were determined using the Kaplan-Meier approach and the log-rank statistic. Cox proportional hazard models with stepwise variable selection (P < 0.10 for inclusion/exclusion) in combination with clinically relevant factors were used to adjust for potential confounders such as differences identified in patient-related, disease-related, or treatment-related factors between both groups. The proportional hazards assumption in these models was assessed using Schoenfeld residuals test, with statistical significance defined as Pr0.05. All analyses were conducted using SAS 9.2 (SAS Institute Inc., Cary, NC) and R software (R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
We identified a total of 118 eligible patients. Twenty-four patients (20%) received IC followed by CRT and 94 (80%) received upfront CRT. Median follow-up in the IC and CRT groups was 17 and 19 months, respectively (P = 0.05). Patient characteristics are described in Table 1 . Disease features and treatment details are presented in Table 2 .
Induction patients were more likely to be male, have higher tumor and nodal stage disease, and less tobacco packyear exposure (Tables 1 and 2 ). The documented intent by the attending medical and/or radiation oncologists for those receiving IC was bulky primary or nodal disease for 18 (75%) patients, and provider preference for 6 (25%) patients. The total treatment time for IC was 16 to 17 weeks (8 wk induction, 1 to 2 wk off, 7 wk CRT) and 7 weeks for CRT. Otherwise, the groups were well balanced with respect to the other diseaserelated and treatment-related factors presented in Table 2 .
Compared with upfront CRT, the use of induction therapy did not affect the total duration of RT, weight loss during RT, delivered RT dose, or the likelihood of lowering the dose of chemotherapy or changing chemotherapy agents during CRT due to toxicity. There were no differences between the groups in the incidence of PEG tube reliance at the date of last follow-up.
Among the 24 patients receiving IC, 7 (29%) had locoregional recurrence, with or without distant metastatic disease, versus 14 of a total of 94 (15%) receiving CRT. All locoregional recurrences were in-field, within the high-dose RT region, an example of which is shown in Figure 1 .
At 18-month follow-up, patients receiving IC had worse overall survival (73% [58% to 93%] vs. 94% [90% to 99%], P = 0.003, Fig. 2A ), locoregional control (58% [36% to 75%] vs. 80% [69% to 88%], P = 0.04, Fig. 2B ), and distant metastasis-free survival (73% [52% to 93%] vs. 96% [92% to 100%], P = 0.007, Fig. 2C ).
Using multivariable Cox regression to adjust for variables that were imbalanced between the 2 groups (T stage, N stage, pack-year smoking history), patients treated with IC had significantly higher risk of locoregional recurrence (HR = 3.6, P = 0.02, Table 3 ), distant metastases (HR = 5.3, P = 0.02, Table 2 ), and worse overall survival (HR = 5.1, P < 0.01, Table 3 ).
DISCUSSION
The results of this study suggest that concurrent CRT should remain the standard organ-preservation treatment option for patients with LA-HNSCC, as previously established. [2] [3] [4] [5] [6] The publication of the TAX studies 7, 8 led to the validation of induction as an alternative approach and TPF as the IC regimen of choice, which was recently validated by a meta-analysis. 16 Acceptance of induction followed by CRT occurred despite the absence of a head-to-head comparison with CRT. The disappointing results from the DeCIDE 9 and PARADIGM 10 randomized trials have tempered the enthusiasm for induction with TPF. A significant limitation of TPF is acute toxicity. In TAX 324, 21% of patients did not proceed to protocol-defined chemoradiotherapy, and 7% of patients did not proceed to any potentially curative therapy, 8 whereas in DeCIDE, there was a significant increase in deaths due to acute toxicity from induction. 9 If the proper role of IC is to be further studied, it is clear that alternatives to current induction regimens will need to be developed.
One such alternative consists of weekly cetuximab, carboplatin, and paclitaxel. This was first studied in a phase II clinical trial published by Kies et al, 12 in which response to induction was 96%, and all 47 patients proceeded to potentially curative therapy. After a median follow-up of 33 months, progression-free and overall survival were 87% and 91%, respectively. Wanebo et al 13 used a similar regimen in 74 patients, in which 65% of patients obtained a pathologic complete response (as assessed by serial biopsies) after induction and a 100% CR rate after subsequent CRT. On the basis of these data, the treating clinicians at our institution selected this regimen as a less toxic and potentially more active alternative to TPF, adopting this latter regimen in 2008 as our preferred approach to IC in the treatment of LA-HNSCC. Our institutional experience with this regimen has demonstrated it to be well tolerated, with response rates similar to those seen with TPF. 14 It is within this context that we present the results of our retrospective, institutional comparison of IC versus CRT, which is notable for its use of a demonstrably less toxic, yet clinically effective alternative induction regimen. We found 8 and occasionally lead to early treatment-related deaths. 9 In our experience, the induction regimen of weekly cetuximab, carboplatin, and paclitaxel was well tolerated. All patients who received induction in our series proceeded to planned CRT. These patients tolerated CRT and their upfront CRT counterparts, as reflected in the similar rates of required changes in chemotherapy dosing or regimen due to toxicity, as well as similar full doses of RT delivered, without treatment delay. We acknowledge that our study findings may be attributable to potential shortcomings such as the retrospective nature of the study and its susceptibility to potential selection bias. Our patients were not randomized, with physician concern about the bulk or volume of the primary and/or nodal disease being the main reason that patients were recommended to receive IC. We controlled for differences in patient-related, disease-related, and treatment-related factors in a multivariable analysis, and found that IC still seemed to be associated with a higher risk of poor disease outcome compared with upfront CRT; however, we acknowledge that even these findings may be due to selection of intrinsically poorer prognosis patients for IC and potential confounding due to unmeasured covariates. Therefore, we do not primarily intend for our study to be a direct head-to-head comparison of IC versus CRT, but rather to direct future discussions on potential novel treatment approaches for LA-HNSCC.
A strength of our study is that it examines the results of IC in a high-risk population. A possible explanation of the negative results from DeCIDE and PARADIGM may be patient selection, as a significant proportion of the patients enrolled may have had a high likelihood of long-term disease control with or without IC (HPV-positive oropharynx patients). Therefore, the benefits of IC may be best realized in a population with high-risk disease features (high T and/or N stage) treated with an induction regimen that is well tolerated and with response rates comparable with the standard, but highly toxic regimen of TPF. The patients in our study who received IC fit such a description. Yet, despite receiving IC, these patients still had suboptimal results, with high rates of locoregional and/or systemic disease recurrence, and poor overall survival.
In conclusion, this study examines treatment with upfront CRT versus a contemporary, promising, and generally welltolerated IC regimen for LA-HNSCC. Despite induction being well tolerated and not compromising subsequent CRT, we observed that patients receiving IC had inferior locoregional and systemic control and overall survival compared with patients receiving upfront CRT; however, given the retrospective nature of this study, selection bias is a potentially significant confounder of our results. Therefore, our findings are strictly hypothesis generating, rather than definitive statements. We did observe that the use of IC in a population selected for high-risk disease features did not appreciably yield significant improvements in disease outcomes. We hope that our results will inform and direct potential future investigations for patients who are at significant risk of disease relapse. We believe that IC may play a role in the treatment of high-risk, LA-HNSCC, but that its use should be in the setting of a randomized, controlled trial. For the time being, we believe concurrent CRT should remain the standard approach for nonsurgical organ preservation in LA-HNSCC. 
